Concurrently, we evaluated the efficacy of OTX008, a pre-existing Gal-1 inhibitor tested for treating advanced solid tumors in 2012 (ClinicalTrials.gov: NCT01724320), against MPNST cells. This evidence concerns the gene LGALS1 and malignant peripheral nerve sheath tumor.